전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved142 programs
AntibodyCurated CorestaleRegeneron PharmaceuticalsPhase 3

Odronextamab (Odronextamab)

Relapsed/Refractory Aggressive B-Cell Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+3
Trials 18Status Recruiting
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Utomilumab (Utomilumab)

Relapsed/Refractory Large B-cell Lymphoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 17Status Active
CGTLimited DatastalePaolo Caimi, MDPhase 1

BAFF CAR-T (BAFF CAR-T)

Relapsed CLL; Refractory CLL · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 15Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

Relapsed and/or Refractory Acute Myeloid Leukemia; High Risk Hematologic Malignancies · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 12Status Active
AntibodyLimited DatastaleGenentech, Inc.Phase 3

Cevostamab (Cevostamab)

Relapsed or Refractory Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#monoclonal-antibody#RelapsedorRefractoryMultipleMyel+1
Trials 10Status Recruiting
CGTLimited DatastaleMiltenyi Biomedicine GmbHPhase 2

MB-CART2019.1 (zamtocabtagene autoleucel, zamtocabtagene autoleucel (MB-CART2019.1))

Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma · B-Cell Neoplasm

#B-CellNeoplasm#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 10Status Recruiting
CGTLimited DatastalePeproMene Bio, Inc.Phase 1

BAFFR-CAR T cells (BAFFR-CAR T cells)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 9Status Recruiting
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Phase 2

Eque-cel (Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection, Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel))

Relapsed/Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 9Status Recruiting
AntibodyLimited DatastaleMacroGenicsPhase 2

Flotetuzumab (Flotetuzumab)

Relapsed Acute Myeloid Leukemia · Relapsed Acute Myeloid Leukemia

#RelapsedAcuteMyeloidLeukemia#Antibody#Phase2#monoclonal-antibody#MacroGenics
Trials 8Status Discontinued
CGTStandard DatabasestaleThe First Hospital of Jilin Uni…Phase 2

IL-15-armored CAR-T cells (IL-15-armored CAR-T cells)

Relapsed/Refractory Multiple Myeloma; Plasma Cell Leukemia (PCL) · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 8Status Recruiting
CGTLimited DatastaleMiltenyi Biotec, Inc.Phase 1

Autologous CAR19 T lymphocytes (Autologous CAR19 T lymphocytes)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 7Status Recruiting
CGTLimited DatastaleShanghai AbelZeta Ltd.Phase 1

C-CAR011 (C-CAR011)

Refractory or Relapsed Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Active
CGTLimited DatastaleShanghai AbelZeta Ltd.Phase 1

C-CAR088 (C-CAR088)

Relapsed or Refractory Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Active
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 6Status Discontinued
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 2

T cell injection targeting CD7 chimeric antigen receptor (T cell injection targeting CD7 chimeric antigen receptor)

CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 6Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

BCMA-CD19 cCAR T cells (BCMA-CD19 cCAR T cells)

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 5Status Recruiting
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

CART22 cells (CART22 cells)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 5Status Discontinued
AntibodyLimited DatastaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 4Status Active
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

CD7CAR T cells (CD7CAR T cells)

Relapsed/Refractory, High Risk Hematologic Malignancies; T-ALL/Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 4Status Active
CGTLimited DatastalePolina StepenskyPhase 2

HBI0101 CART (HBI0101 CART)

Multiple Myeloma, Refractory to Standard Treatment; Multiple Myeloma, Relapsed · Systemic Sclerosis (SSc)

#SystemicSclerosisSSc#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 4Status Recruiting

2 / 8 pages

← PreviousNext →